Glaxo receives FDA 'complete response' for cervical cancer vaccine

Dec 17 2007 - 8:24am
Advertisement

GlaxoSmithKline (NYSE: GSK) announced today that it has received a complete response letter from the U.S. Food and Drug Administration related to its application for the cervical cancer vaccine, CERVARIX

Share this content.

Contact Us To Be Mentioned in EmaxHealth.com
Advertisement